Classification of mitocans, anti-cancer drugs acting on mitochondria

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F13%3A00393079" target="_blank" >RIV/86652036:_____/13:00393079 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.mito.2012.07.112" target="_blank" >http://dx.doi.org/10.1016/j.mito.2012.07.112</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.mito.2012.07.112" target="_blank" >10.1016/j.mito.2012.07.112</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Classification of mitocans, anti-cancer drugs acting on mitochondria

Popis výsledku v původním jazyce

Mitochondria have emerged as an intriguing target for anti-cancer drugs, inherent to vast majority if not all types of tumours. Drugs that target mitochondria and exert anti-cancer activity have become a focus of recent research due to their great clinical potential (which has not been harnessed thus far). The exceptional potential of mitochondria as a target for anti-cancer agents has been reinforced by the discouraging finding that even turnouts of the same type from individual patients differ in a number of mutations. This is consistent with the idea of personalised therapy, an elusive goal at this stage, in line with the notion that tumours are unlikely to be treated by agents that target only a single gene or a single pathway. This endows mitochondria, an invariant target present in all tumours, with an exceptional momentum. This train of thoughts inspired us to define a class of anti-cancer drugs acting by way of mitochondria 'destabilisation', termed 'mitocans'. In this communic

Název v anglickém jazyce

Classification of mitocans, anti-cancer drugs acting on mitochondria

Popis výsledku anglicky

Mitochondria have emerged as an intriguing target for anti-cancer drugs, inherent to vast majority if not all types of tumours. Drugs that target mitochondria and exert anti-cancer activity have become a focus of recent research due to their great clinical potential (which has not been harnessed thus far). The exceptional potential of mitochondria as a target for anti-cancer agents has been reinforced by the discouraging finding that even turnouts of the same type from individual patients differ in a number of mutations. This is consistent with the idea of personalised therapy, an elusive goal at this stage, in line with the notion that tumours are unlikely to be treated by agents that target only a single gene or a single pathway. This endows mitochondria, an invariant target present in all tumours, with an exceptional momentum. This train of thoughts inspired us to define a class of anti-cancer drugs acting by way of mitochondria 'destabilisation', termed 'mitocans'. In this communic

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mitochondrion

ISSN

1567-7249

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

199-208

Kód UT WoS článku

000317445700007

EID výsledku v databázi Scopus

—